In pursuance of Regulation 33(3)(C) of the LODR with Stock Exchange, Bharat Immunologicals & Biologicals Corporation has informed about submission of the Limited Review Report along with the financial results for the Quarter ended 30th June 2019.
The above information is a part of company’s filings submitted to BSE.